CD7 targeted CAR-γδ T cells therapy(Persongen Bio)

N/A

Report date: 2024/11/24 20:00:04

Base Information

Drug NameCD7 targeted CAR-γδ T cells therapy(Persongen Bio)
Drug Alias NameCD7-targetting chimeric antigen receptor γδ T cell therapy (Persongen Bio)CD7 targeted gamma delta CAR-T cell therapy
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT-cell antigen CD7 inhibitorsCell replacements
TargetsT-cell antigen CD7
Therapy Area/IndicationsLeukemia, B-CellNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesPersongen Biotherapeutics (Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPersongen Biotherapeutics (Suzhou) Co Ltd
Active IndicationsN/A
Inactive IndicationsLeukemia, B-CellNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A